Ribociclib/Fulvestrant Combo Improves OS in Advanced HR+ Breast Cancer
September 29th 2019The combination of ribociclib and fulvestrant led to an approximate 28% reduction in the risk of death compared with placebo and fulvestrant in postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer.
Neoadjuvant Pembrolizumab Combo Prolongs pCR in Phase III TNBC Study
Neoadjuvant treatment with the combination of pembrolizumab and chemotherapy extended pathological complete response rates by 13.6 percentage points compared with chemotherapy alone for patients with early triple-negative breast cancer.
Enfortumab Vedotin Plus Pembrolizumab Shows Promise in Urothelial Cancer
More than 70% of patients with cisplatin-ineligible locally advanced urothelial cancer had objective responses to the investigational antibody-drug conjugate enfortumab vedotin plus pembrolizumab (Keytruda).
Frontline Olaparib/Bevacizumab Maintenance Combo Extends PFS in Ovarian Cancer
Frontline maintenance therapy with the combination of olaparib and bevacizumab improved median progression-free survival versus bevacizumab and placebo for patients with newly diagnosed, advanced ovarian cancer.
Frontline Nivolumab/Ipilimumab Combo Improves OS in Advanced NSCLC
September 28th 2019The first-line combination of nivolumab and ipilimumab led to a clinically meaningful improvement in overall survival versus chemotherapy in patients with advanced non–small cell lung cancer, regardless of PD-L1 expression.
Niraparib Improves PFS as Frontline Maintenance in Ovarian Cancer
Frontline maintenance therapy with the PARP inhibitor niraparib improved median progression-free survival by 5.6 months compared with placebo for patients with newly diagnosed, advanced ovarian cancer who responded to platinum-based chemotherapy.
Frontline Veliparib Shows Intriguing PFS Findings in VELIA Trial
The frontline combination of veliparib, carboplatin, and paclitaxel followed by maintenance veliparib monotherapy led to a 32% reduction in the risk of progression or death compared with placebo plus chemotherapy with placebo maintenance for patients with high-grade serous ovarian cancer.
Telaglenastat Plus Everolimus Emerges as Novel Approach in Metastatic RCC
Adding the investigational glutaminase inhibitor telaglenastat to everolimus extends progression-free survival compared with everolimus alone in patients with heavily pretreated advanced renal cell carcinoma.
Cediranib/Olaparib Combo Shows Promise in Platinum-Resistant Ovarian Cancer
The combination of cediranib and olaparib improved progression-free survival in patients with platinum-resistant ovarian cancer, although the difference from chemotherapy did not achieve statistical significance.
ESMO Data Show More Can Be Done for Cancer of Unknown Primary Patients
September 28th 2019Two research papers presented by Roche and Foundation Medicine at the 2019 European Society of Medical Oncology (ESMO) Annual Meeting demonstrate both the promise of an innovative precision medicine driven clinical trial for patients with cancer of unknown primary, as well as the challenges of identifying eligible patients for the trial, according to ESMO guidelines.
Atezolizumab Plus Bevacizumab Impresses in Unresectable HCC
Patients with unresectable hepatocellular carcinoma obtained clinically meaningful responses and statistically significant improvement in progression-free survival with the combination of atezolizumab and bevacizumab.
Pemigatinib Active as Second-Line Treatment for FGFR2+ Cholangiocarcinoma
More than one-third of patients with previously treated locally advanced or metastatic cholangiocarcinoma with an FGFR2 rearrangement or fusion had durable objective responses to treatment with pemigatinib.
Apalutamide Linked to OS Benefit in Nonmetastatic CRPC
September 27th 2019The next-generation androgen receptor apalutamide, in combination with androgen deprivation therapy, demonstrated a 25% reduction in the risk of death compared with placebo/ADT in patients with nonmetastatic castration-resistant prostate cancer in the phase III SPARTAN trial.
Dr. Choueiri on the Impact of the JAVELIN Renal 101 Findings in RCC
October 25th 2018Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the impact of the JAVELIN Renal 100 trial on the treatment landscape of renal cell carcinoma.
Dr. Mehanna on the Updated Staging System for HPV+ Head and Neck Cancer
October 25th 2018Hisham Mehanna, PhD, BMedSc, MBChB, FRCS, chair, Head and Neck Surgery director, Institute of Head and Neck Studies and Education at the School of Cancer Studies, University of Birmingham, discusses the new staging system for patients with HPV-positive head and neck cancer.
Frontline Alectinib Outperforms Crizotinib in Asian Patients With ALK+ NSCLC
Asian patients with untreated ALK-positive advanced NSCLC lived significantly longer without disease progression if they received the next-generation tyrosine kinase inhibitor alectinib instead of crizotinib as initial therapy.
Neoadjuvant Nivolumab Plus Ipilimumab Active in dMMR Early-Stage Colon Cancer
First results from a study of neoadjuvant ipilimumab plus nivolumab in patients with early-stage colon cancer found a major pathologic response achieved in all 7 patients with mismatch repair deficient tumors.
Frontline Atezolizumab Plus Carboplatin/Nab-Paclitaxel Improves OS in Nonsquamous NSCLC
October 22nd 2018The first-line triplet of atezolizumab, carboplatin, and nab-paclitaxel was associated with a statistically significant improvement in both progression-free and overall survival compared with chemotherapy alone in patients with stage IV nonsquamous NSCLC, according to results from the phase III IMpower130 trial.